Key result
Tirofiban linked to ~108% higher odds of excellent 90-day outcomes in anterior stroke with severe stenosis.
Why the study?
The authors aimed to evaluate neuroimaging characteristics and their clinical significance to guide tirofiban treatment in patients with acute ischemic stroke who did not undergo early recanalization treatments.
Does tirofiban improve functional outcomes at 90 days in acute ischemic stroke patients who did not undergo early recanalization treatments, based on neuroimaging features?
Population
AIS patients who did not undergo early recanalization treatments
Comparison
Tirofiban vs control group stratified by neuroimaging features
Design
Post hoc analysis of a clinical trial
Follow-up
90 days
Authors
Loading...
Tirofiban was associated with better 90-day outcomes in this subgroup; hypothesis-generating and requires randomized confirmation before practice change.
Does tirofiban improve functional outcomes at 90 days in acute ischemic stroke patients who did not undergo early recanalization treatments, based on neuroimaging features?
Odds Ratio: 2.08 (95% CI 1.25–3.45)
p-value: p=0.004
Tirofiban improves 90-day functional outcomes in acute ischemic stroke patients with anterior circulation stroke and severe stenosis who do not undergo early recanalization.
Han et al. (2023) studied acute ischemic stroke (AIS). Tirofiban vs. control group was evaluated on excellent functional outcome (modified Rankin Scale score of 0-1) at 90 days in anterior circulation stroke patients (OR 2.08, 95% CI 1.25-3.45, p=0.004). Tirofiban improved excellent functional outcomes at 90 days in acute ischemic stroke patients with anterior circulation stroke (OR 2.08; 95% CI 1.25-3.45; p=0.004) and severe stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: